Joylux: Who Should Avoid It and Is It Legit?

What Is Joylux and What Does the vFit Actually Do?

Joylux is a Seattle-based direct-to-consumer intimate wellness company whose flagship product, the vFit, delivers low-level red light (photobiomodulation), gentle heat, and vibration inside the vaginal canal. The company targets perimenopausal and postmenopausal women experiencing genitourinary syndrome of menopause (GSM), a condition affecting an estimated 45% of postmenopausal women and characterized by vaginal dryness, painful sex, and recurrent urinary symptoms.

The device is not a prescription laser. It does not deliver the same energy as in-office fractional CO2 or Er:YAG devices. Understanding that distinction matters because it shapes both what the vFit might reasonably do and what regulatory category it sits in.

How Photobiomodulation Works in Theory

Red-light wavelengths in the 630-850 nm range are thought to stimulate cytochrome c oxidase in mitochondria, potentially increasing collagen synthesis and local circulation. Animal and in-vitro data support this mechanism, but translation to human vaginal tissue is not yet confirmed by independent large-scale trials.

What Joylux's Own Evidence Shows

Joylux has published a small pilot study. The company-funded 2020 study enrolled 35 postmenopausal women and reported improvements in the Female Sexual Function Index (FSFI) and the Vaginal Health Index after 60 days of use. The result is clinically interesting but the sample is small, there was no placebo arm, and the study was funded by the manufacturer. Independent replication in a blinded RCT has not yet appeared in the peer-reviewed literature. The Menopause Society's 2023 position statement on energy-based devices notes that evidence for low-energy consumer devices remains insufficient to recommend them over established therapies.

Is Joylux Legit? An Independent Assessment

"Legit" covers at least three separate questions: Is the company real and accountable? Is the device safe? Does it work as advertised?

Company Legitimacy

Joylux, Inc. Holds a Better Business Bureau accreditation with an A rating. Consumer complaint categories on file with the BBB center on return policy disputes, subscription auto-enrollment, and delayed refunds, not reports of physical injury from the device itself. The company is not listed on the FDA's database of warning letters as of this article's review date, which is a positive signal. LegitScript, the pharmacy and healthcare verification service, does not classify Joylux as a rogue or unapproved seller.

Regulatory Standing

The vFit is sold as a wellness device, not a medical device cleared by the FDA for the treatment of GSM, sexual dysfunction, or urinary incontinence. This is not automatically a red flag. Many legitimate consumer wellness tools occupy this space. What it does mean is that Joylux cannot legally claim it treats or cures any of those conditions, and you should weigh any such language in marketing copy accordingly. The FDA's digital health and wellness device framework does not require premarket clearance for low-risk devices that do not claim to diagnose, cure, treat, or prevent disease.

The Honest Evidence Gap

A useful framework for evaluating any intimate wellness device is to ask three questions in sequence. First, does the mechanism have plausible biological support? For photobiomodulation, the answer is yes in theory but unconfirmed in adequately powered vaginal tissue RCTs. Second, does the company-funded pilot data point in a meaningful direction? For vFit, the FSFI signal is modest and consistent with what you would hope to see, but a 35-person unblinded study cannot carry much weight. Third, has any independent group replicated the finding with a control arm? As of July 2025, the answer is no. Women have been historically under-represented in device trials, and GSM specifically was not even named as a clinical entity until 2014, meaning the entire evidence base for vaginal energy-based therapies is young and thin regardless of which brand you are evaluating.

Who Should Not Use Joylux: Specific Patient Profiles to Avoid

This is the most clinically consequential section of this article. Several patient profiles carry real contraindications or strong cautions. If you fall into any of these groups, you should speak with your clinician before purchasing or using the vFit.

Active or Recent Pelvic or Gynecologic Cancer

Any woman with a current diagnosis of cervical, uterine, ovarian, vaginal, or vulvar cancer, or who has completed treatment within the past 12 months, should not use this device. Photobiomodulation and thermal stimulation have not been studied in this population. The concern is theoretical but meaningful: localized energy delivery near tissue with residual malignant or premalignant changes is not a risk worth taking without explicit oncologist clearance. ACOG's guidance on survivorship care emphasizes individualized discussion with the oncology team before initiating any new vaginal intervention.

Pregnancy

The vFit is contraindicated in pregnancy. No safety data exists for thermal or photobiomodulation vaginal devices in pregnant women, and the combination of intravaginal heat and vibration presents an untested risk to developing tissue. Joylux's own labeling excludes pregnant users. If there is any chance you are pregnant, do not use this device.

Active Vaginal or Pelvic Infection

An active yeast infection, bacterial vaginosis, trichomoniasis, genital herpes outbreak, or pelvic inflammatory disease is a firm contraindication. Inserting a device into an infected canal can mechanically spread pathogens, disrupt healing tissue, and introduce secondary infection. Wait until infection is fully resolved and confirmed by your provider before resuming or starting use.

Pelvic Implants and Certain IUDs

Women with metallic pelvic implants, mesh, or certain intrauterine devices should confirm device compatibility before use. The vFit's thermal component raises a theoretical concern with metal-containing implants in the treatment zone. Hormonal and copper IUDs sit in the uterine cavity, not the vaginal canal, so they are generally not in the direct treatment field, but you should confirm placement and discuss with your gynecologist if you have any doubt.

Photosensitizing Medications

If you take a medication that causes photosensitivity, including certain tetracyclines, fluoroquinolones, thiazide diuretics, NSAIDs, or retinoids, the interaction with red-light wavelengths delivered intravaginally has not been studied. The mucosal tissue of the vaginal canal is far more absorptive than skin. Exercise caution and check with your prescriber.

Active Pelvic Organ Prolapse Stage III or IV

Women with advanced prolapse have significantly altered vaginal anatomy. Device insertion in stage III or IV prolapse may be uncomfortable, may not deliver energy to the intended tissue, and has not been studied in this population. A urogynecologist visit to assess prolapse stage and appropriateness is warranted before attempting use.

Vulvodynia and Vestibulodynia

Women with chronic vulvar pain conditions may find insertion painful and may experience a flare following any intravaginal device use. The heat component in particular could aggravate sensitized tissue. This is not a hard contraindication in all cases, but it warrants a pain-specialist discussion.

Life-Stage Guide: When the vFit Is and Is Not Appropriate

Reproductive Years (Roughly Ages 18-40)

The vFit was not designed or studied for reproductive-age women without GSM. Vaginal dryness or pain with sex in this group often has a different cause: low-dose hormonal contraception, postpartum estrogen suppression, stress, or an undiagnosed condition like lichen sclerosus. Using a photobiomodulation device without addressing those root causes delays effective treatment. If you are in your reproductive years and experiencing vaginal symptoms, a gynecologic evaluation should come before any device purchase.

Trying to Conceive

There is no data on vFit use during active conception attempts. Because the device delivers intravaginal heat, and because sperm and early embryos are sensitive to thermal changes, the cautious position is to avoid use in the luteal phase of any cycle in which conception is possible.

Postpartum and Lactation

Postpartum vaginal dryness is extremely common and is driven by the same low-estrogen state as menopause. Breastfeeding suppresses estradiol substantially, with levels sometimes dropping below 30 pg/mL, causing GSM-like symptoms. The vFit has not been studied in this population. Postpartum pelvic floor tissue is also healing, particularly after vaginal delivery or episiotomy. The general recommendation is to wait until at least 6 weeks postpartum and to have a pelvic floor assessment before introducing any intravaginal device. Vaginal estrogen, which is safe in lactation at low doses per ACOG's postpartum guidance, is often a more evidence-supported first-line option for lactation-related dryness.

Perimenopause (Roughly Ages 40-52)

This is the group for whom the vFit is most actively marketed and who may derive real, if modest, benefit. Estrogen fluctuation during perimenopause produces intermittent vaginal dryness and changes in lubrication that precede the more severe GSM of full menopause. A device that improves local circulation and mucosal health fits the biology of this stage, in theory. The evidence gap remains. Before spending several hundred dollars, consider whether you have discussed vaginal estrogen, ospemifene, or a vaginal moisturizer with your clinician. These options have substantially stronger evidence bases than any at-home energy device.

Postmenopause

Postmenopausal women with GSM are the core intended users. If you have exhausted first-line options, have contraindications to local estrogen (for example, certain hormone-receptor-positive breast cancers where even low-dose vaginal estrogen remains a point of clinical debate), or are seeking a non-hormonal adjunct, the vFit represents a low-risk addition to your management plan, provided none of the contraindications above apply to you. Keep realistic expectations: the 35-person pilot study reported modest FSFI improvement, not resolution of severe symptoms.

Pregnancy and Lactation Safety

Pregnancy: Contraindicated. Joylux does not provide safety data for use during pregnancy, and no independent research has evaluated intravaginal photobiomodulation or thermal devices in pregnant women. The device must not be used during pregnancy.

Lactation: No data exists on whether red-light or thermal vaginal stimulation produces any systemic effect that would affect breast milk. The primary concern in lactating women is anatomical: postpartum tissue is still healing, and low estrogen from lactation makes vaginal mucosa thin and more easily irritated. If you are breastfeeding and experiencing vaginal dryness, discuss low-dose vaginal estradiol or vaginal DHEA with your provider before turning to a device.

Contraception note: The vFit is not a contraceptive and does not affect fertility in any known direction. If you are using a hormonal contraceptive that causes vaginal dryness (a documented side effect of low-estrogen pills and the levonorgestrel IUD in some users), address the hormonal cause first.

Common Joylux Complaints and What They Actually Mean

Consumer complaint data from the BBB and online forums clusters into three categories.

The first and most common complaint is about return policy and billing. Joylux operates a subscription model for the vFit Plus gel. Several users report difficulty canceling and unexpected charges. This is a customer service issue, not a safety issue, but it is worth reading the fine print before purchasing.

The second complaint category is unmet expectations. Women report purchasing the device expecting significant improvement in dryness or orgasm intensity and finding the results modest or absent. This is consistent with the evidence: a device supported by a single 35-person uncontrolled pilot study should carry modest expectations. Managing expectations before purchase is the right move.

The third category is discomfort with use. A subset of users reports insertion discomfort or increased irritation. This may reflect undiagnosed vulvodynia, active irritation, or simply that the device is not anatomically compatible with every user. Discomfort should prompt you to stop use and speak with a pelvic health specialist.

No reports of serious physical injury from correct device use appear in FDA's MAUDE database search results for Joylux as of this review. That is a meaningful absence, though MAUDE is a passive surveillance system and under-reporting is common.

How Joylux Compares to Established Treatments for GSM

Before spending $300-$500 on a device with limited evidence, you deserve to know what the alternatives look like.

| Treatment | Evidence Level | Cost | Prescription Required | |---|---|---|---| | Vaginal estradiol (cream, ring, tablet) | High; multiple RCTs | Low | Yes | | Ospemifene (Osphena) | High; FDA-approved | Moderate | Yes | | Vaginal DHEA (Intrarosa) | High; FDA-approved | Moderate | Yes | | Vaginal moisturizer (polycarbophil, hyaluronic acid) | Moderate | Low | No | | In-office fractional CO2 laser | Moderate; FDA cleared for gynecologic use | High | No (provider-administered) | | vFit (Joylux) | Low; single small manufacturer-funded study | High | No |

The Menopause Society's 2023 position statement on GSM identifies vaginal estrogen as the most effective treatment for moderate-to-severe symptoms. Consumer energy devices are not listed as first-line or second-line options.

What to Discuss With Your Clinician Before Buying

Bring these five questions to your next gynecology or menopause specialist visit.

1. Have we identified why I have vaginal dryness or pain? Is it GSM, a medication side effect, or something else?
2. Am I a candidate for vaginal estrogen or ospemifene, and if not, why not?
3. Do I have any of the contraindications to an at-home photobiomodulation device?
4. If I want to try the vFit anyway, should I use it alongside or instead of other treatments?
5. How will we know if it is working, and what is the timeline for reassessment?

A 2022 survey published in Menopause found that fewer than 30% of women with GSM symptoms had ever been asked about them by their provider, and fewer than 15% had initiated the conversation themselves. Your symptoms are worth raising. Direct language works: "I have vaginal dryness and pain with sex. What are my options?"